Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Toward a system of microbial forensics: from sample collection to interpretation of evidence.

Budowle B, Schutzer SE, Ascher MS, Atlas RM, Burans JP, Chakraborty R, Dunn JJ, Fraser CM, Franz DR, Leighton TJ, Morse SA, Murch RS, Ravel J, Rock DL, Slezak TR, Velsko SP, Walsh AC, Walters RA.

Appl Environ Microbiol. 2005 May;71(5):2209-13. Review. No abstract available.

2.

Predictors of severe morbidity and death after elective abdominal aortic aneurysmectomy in patients with chronic obstructive pulmonary disease.

Upchurch GR Jr, Proctor MC, Henke PK, Zajkowski P, Riles EM, Ascher MS, Eagleton MJ, Stanley JC.

J Vasc Surg. 2003 Mar;37(3):594-9.

3.

Hemorrhagic fever viruses as biological weapons: medical and public health management.

Borio L, Inglesby T, Peters CJ, Schmaljohn AL, Hughes JM, Jahrling PB, Ksiazek T, Johnson KM, Meyerhoff A, O'Toole T, Ascher MS, Bartlett J, Breman JG, Eitzen EM Jr, Hamburg M, Hauer J, Henderson DA, Johnson RT, Kwik G, Layton M, Lillibridge S, Nabel GJ, Osterholm MT, Perl TM, Russell P, Tonat K; Working Group on Civilian Biodefense.

JAMA. 2002 May 8;287(18):2391-405. Review.

PMID:
11988060
4.

Anthrax as a biological weapon, 2002: updated recommendations for management.

Inglesby TV, O'Toole T, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Gerberding J, Hauer J, Hughes J, McDade J, Osterholm MT, Parker G, Perl TM, Russell PK, Tonat K; Working Group on Civilian Biodefense.

JAMA. 2002 May 1;287(17):2236-52. Review. Erratum in: JAMA 2002 Oct 16;288(15):1849.

PMID:
11980524
5.

Tularemia as a biological weapon: medical and public health management.

Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, Lillibridge SR, McDade JE, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K; Working Group on Civilian Biodefense.

JAMA. 2001 Jun 6;285(21):2763-73. Review.

PMID:
11386933
6.

Botulinum toxin as a biological weapon: medical and public health management.

Arnon SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J, Layton M, Lillibridge S, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Swerdlow DL, Tonat K; Working Group on Civilian Biodefense.

JAMA. 2001 Feb 28;285(8):1059-70. Review. Erratum in: JAMA 2001 Apr 25;285(16):2081.

PMID:
11209178
7.

Limitations of plasma human immunodeficiency virus RNA testing.

Krowka JF, Sheppard HW, Ascher MS, Hallowitz R.

Clin Infect Dis. 2000 Nov;31(5):1317-8. No abstract available.

PMID:
11073782
8.

Bioterrorism initiatives: public health support.

Perrotta DM, Ascher MS, Layton M.

Am J Public Health. 2000 Aug;90(8):1327-8. No abstract available.

9.

A civilian-military virtual public health laboratory network.

Ascher MS.

Mil Med. 2000 Jul;165(7 Suppl 2):1-4. No abstract available.

PMID:
10920627
10.

Plague as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Inglesby TV, Dennis DT, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Koerner JF, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Schoch-Spana M, Tonat K.

JAMA. 2000 May 3;283(17):2281-90. Review.

PMID:
10807389
11.

Smallpox as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J, Layton M, McDade J, Osterholm MT, O'Toole T, Parker G, Perl T, Russell PK, Tonat K.

JAMA. 1999 Jun 9;281(22):2127-37. Review.

PMID:
10367824
12.

Anthrax as a biological weapon: medical and public health management. Working Group on Civilian Biodefense.

Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Friedlander AM, Hauer J, McDade J, Osterholm MT, O'Toole T, Parker G, Perl TM, Russell PK, Tonat K.

JAMA. 1999 May 12;281(18):1735-45. Review. Erratum in: JAMA 2000 Apr 19;283(15):1963.

PMID:
10328075
13.

Prevalence and correlates of hepatitis C virus infection among inmates entering the California correctional system.

Ruiz JD, Molitor F, Sun RK, Mikanda J, Facer M, Colford JM Jr, Rutherford GW, Ascher MS.

West J Med. 1999 Mar;170(3):156-60.

14.

Direct HIV cytopathicity cannot account for CD4 decline in AIDS in the presence of homeostasis: a worst-case dynamic analysis.

Anderson RW, Ascher MS, Sheppard HW.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Mar 1;17(3):245-52. Review.

PMID:
9495225
15.

Lack of associations of chemotactic cytokines with viral burden, disease progression, or lymphocyte subsets in HIV-infected individuals.

Krowka JF, Gesner ML, Ascher MS, Sheppard HW.

Clin Immunol Immunopathol. 1997 Oct;85(1):21-7.

PMID:
9325065
16.

Seroepidemiologic studies of hantavirus infection among wild rodents in California.

Jay M, Ascher MS, Chomel BB, Madon M, Sesline D, Enge BA, Hjelle B, Ksiazek TG, Rollin PE, Kass PH, Reilly K.

Emerg Infect Dis. 1997 Apr-Jun;3(2):183-90. Review.

17.

Immunotherapy for HIV.

Krowka JF, Sheppard HW, Ascher MS.

Lancet. 1997 Feb 8;349(9049):434. No abstract available.

PMID:
9033497
18.

The lack of association of marijuana and other recreational drugs with progression to AIDS in the San Francisco Men's Health Study.

Di Franco MJ, Sheppard HW, Hunter DJ, Tosteson TD, Ascher MS.

Ann Epidemiol. 1996 Jul;6(4):283-9.

PMID:
8876838
19.

A human case of monocytic ehrlichiosis with adult respiratory distress syndrome in northern California.

Vugia DJ, Holmberg E, Steffe EM, Ascher MS, Gallo D.

West J Med. 1996 Jun;164(6):525-8. No abstract available.

20.

Epidemiologic linkage of rodent and human hantavirus genomic sequences in case investigations of hantavirus pulmonary syndrome.

Hjelle B, Tórrez-Martínez N, Koster FT, Jay M, Ascher MS, Brown T, Reynolds P, Ettestad P, Voorhees RE, Sarisky J, Enscore RE, Sands L, Mosley DG, Kioski C, Bryan RT, Sewell CM.

J Infect Dis. 1996 Apr;173(4):781-6.

PMID:
8603954
21.

Expression of CD69 after in vitro stimulation: a rapid method for quantitating impaired lymphocyte responses in HIV-infected individuals.

Krowka JF, Cuevas B, Maron DC, Steimer KS, Ascher MS, Sheppard HW.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Jan 1;11(1):95-104.

PMID:
8528739
22.

HIV results in the frame. Paradox remains.

Ascher MS, Sheppard HW, Anderson RW, Krowka JF, Bremermann HJ.

Nature. 1995 May 18;375(6528):196; author reply 198. No abstract available.

PMID:
7746317
23.

Response.

Ascher MS, Sheppard HW, Winkelstein W Jr.

Science. 1995 Apr 21;268(5209):351-2. No abstract available.

PMID:
17746529
24.

AIDS-associated Kaposi's sarcoma. "Duesberg phenomenon'.

Ascher MS, Sheppard HW.

Science. 1995 Feb 24;267(5201):1080. No abstract available.

PMID:
7726989
25.

Isolation and initial characterization of a newfound hantavirus from California.

Schmaljohn AL, Li D, Negley DL, Bressler DS, Turell MJ, Korch GW, Ascher MS, Schmaljohn CS.

Virology. 1995 Feb 1;206(2):963-72.

26.

AIDS as immune system activation. Key questions that remain.

Ascher MS, Sheppard HW, Krowka JF, Bremermann HJ.

Adv Exp Med Biol. 1995;374:203-10. Review.

PMID:
7572393
27.

Hantavirus pulmonary syndrome in California: report of two cases and investigation.

Shefer AM, Tappero JW, Bresee JS, Peters CJ, Ascher MS, Zaki SR, Jackson RJ, Werner SB, Rollin PE, Ksiazek TG, et al.

Clin Infect Dis. 1994 Dec;19(6):1105-9.

PMID:
7888541
28.

The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels.

Sheppard HW, Lang W, Ascher MS, Vittinghoff E, Winkelstein W.

AIDS. 1993 Sep;7(9):1159-66.

PMID:
8105806
29.

Viral burden and HIV disease.

Sheppard HW, Ascher MS, Krowka JF.

Nature. 1993 Jul 22;364(6435):291-2. No abstract available.

PMID:
8101354
30.

Aetiology of AIDS.

Ascher MS, Sheppard HW, Winkelstein W Jr, Vittinghoff E.

Lancet. 1993 May 8;341(8854):1223. No abstract available.

PMID:
8098119
31.

Does drug use cause AIDS?

Ascher MS, Sheppard HW, Winkelstein W Jr, Vittinghoff E.

Nature. 1993 Mar 11;362(6416):103-4.

PMID:
8095697
32.

Use of T lymphocyte subset analysis in the case definition for AIDS.

Sheppard HW, Ascher MS, Winkelstein W Jr, Vittinghoff E, Osmond D, Moss AR, Shiboski S.

J Acquir Immune Defic Syndr. 1993 Mar;6(3):287-94.

PMID:
8383733
33.
34.

Prevalence of human T cell lymphotropic virus types 1 and 2 (HTLV-1/2) in selected Tijuana subpopulations.

Guerena-Burgueno F, Benenson AS, Sepulveda-Amor J, Ascher MS, Vugia DJ, Gallo D.

Am J Trop Med Hyg. 1992 Aug;47(2):127-32.

PMID:
1503181
35.

Analytic results of HIV-1 testing using blind proficiency testing.

Peddecord KM, Benenson AS, Hofherr LK, Francis DP, Garfein RS, Ferran KL, Taylor RN, Schalla WO, Ascher MS.

Clin Lab Sci. 1992 May-Jun;5(3):165-71.

PMID:
10147724
36.

A comparison of HIV-1, HBV, and HTLV-I/II seroprevalence rates of injured patients admitted through California emergency departments.

Rhee KJ, Albertson TE, Kizer KW, Burns MJ, Hughes MJ, Ascher MS.

Ann Emerg Med. 1992 Apr;21(4):397-401.

PMID:
1554177
37.

Seroprevalence of HIV-type 1 in a northern California health plan population: an unlinked survey.

Hiatt RA, Capell FJ, Ascher MS.

Am J Public Health. 1992 Apr;82(4):564-7.

38.

Distribution of HIV type 1 infection in childbearing women in California.

Capell FJ, Vugia DJ, Mordaunt VL, Marelich WD, Ascher MS, Trachtenberg AI, Cunningham GC, Arnon SS, Kizer KW.

Am J Public Health. 1992 Feb;82(2):254-6.

39.

The relationship between AIDS and immunologic tolerance.

Sheppard HW, Ascher MS.

J Acquir Immune Defic Syndr. 1992;5(2):143-7. Review.

PMID:
1732506
40.

The natural history and pathogenesis of HIV infection.

Sheppard HW, Ascher MS.

Annu Rev Microbiol. 1992;46:533-64. Review.

PMID:
1444266
41.

AIDS and programmed cell death.

Sheppard HW, Ascher MS.

Immunol Today. 1991 Nov;12(11):423. No abstract available.

PMID:
1786077
42.
43.

Immune response to HIV p24 core protein during the early phases of human immunodeficiency virus infection.

McRae B, Lange JA, Ascher MS, de Wolf F, Sheppard HW, Goudsmit J, Allain JP.

AIDS Res Hum Retroviruses. 1991 Aug;7(8):637-43.

PMID:
1931233
44.

A multicenter proficiency trial of gene amplification (PCR) for the detection of HIV-1.

Sheppard HW, Ascher MS, Busch MP, Sohmer PR, Stanley M, Luce MC, Chimera JA, Madej R, Rodgers GC, Lynch C, et al.

J Acquir Immune Defic Syndr. 1991;4(3):277-83.

PMID:
1992104
45.

A unified hypothesis for three cardinal features of HIV immunology.

Ascher MS, Sheppard HW.

J Acquir Immune Defic Syndr. 1991;4(1):97-8. No abstract available.

PMID:
1984060
46.

Viral burden in HIV disease.

Ascher MS, Sheppard HW, Arnon JM, Lang W.

J Acquir Immune Defic Syndr. 1991;4(8):824-5. No abstract available.

PMID:
1677421
47.

The initial immune response to HIV and immune system activation determine the outcome of HIV disease.

Sheppard HW, Ascher MS, McRae B, Anderson RE, Lang W, Allain JP.

J Acquir Immune Defic Syndr. 1991;4(7):704-12.

PMID:
1675678
48.

The trouble with T cells.

Ascher MS, Sheppard HW.

Lancet. 1990 Aug 25;336(8713):507. No abstract available.

PMID:
1975012
49.

Immunofluorescence for serodiagnosis of retrovirus infection.

Ascher MS, Wilber JC.

Arch Pathol Lab Med. 1990 Mar;114(3):246-8. Review.

PMID:
2154960
50.

AIDS as immune system activation. II. The panergic imnesia hypothesis.

Ascher MS, Sheppard HW.

J Acquir Immune Defic Syndr. 1990;3(2):177-91. Review.

PMID:
2404100

Supplemental Content

Loading ...
Support Center